Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, 210006, China
Location status: Recruiting
Location contact
Junshan Zhou, M.D.
CONTACT
Qiwen Deng, M.D.
CONTACT
NCT Number: NCT04230785
EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. The candidate circRNA/lncRNA/miRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.
Interested in participating?
Request Info18 year–90 year
All sexes
Observational
Nanjing, Jiangsu, 210006, China
Location status: Recruiting
Junshan Zhou, M.D.
CONTACT
Qiwen Deng, M.D.
CONTACT
Noncoding RNAs have been highlighted to be involved in the pathological process of ischemic stroke (IS). The purpose of this protocol will investigate the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. The candidate circRNA/lncRNA/miRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke. Distinctive expression patterns of circRNA/miRNA/lncRNA will be identified by the next-generation sequencing and individual quantitative real time polymerase chain reaction (qRT-PCR). A predictive model will be established using logistic regression. The panel of these altered ncRNAs may be associated with the immune status after acute IS and could serve as a regulator for progression and prognosis of acute ischemic stroke with endovascular treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
Other names: Quantitative Real-time polymerase chain reaction
Time frame: 90 days
Differential expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) will be compared in acute ischemic stroke patients before and after endovascular treatment, thus candidate circRNA/lncRNA/miRNA will be verified as biomarkers and regulators for progression and prognosis of acute ischemic stroke with endovascular treatment.
Time frame: 90 days
The prognosis of AIS patients will be analyzed between differential expressed candidate circRNA/lncRNA/miRNA after they have endovascular treatment.
Time frame: 90 days
Correlation of circRNA/lncRNA/miRNA and inflammatory factors in acute ischemic stroke before and after endovascular treatment will be explored.
Time frame: 90 days
Correlation of circRNA/lncRNA/miRNA and stroke-associated infection will be explored in acute ischemic stroke with endovascular treatment.
Time frame: 90 days
Dynamic changes of circRNA/lncRNA/miRNA will be explored after endovascular therapy during the follow-up period
Contact information is provided by the study sponsor or research team.
Junshan Zhou, M.D
CONTACT
Qiwen Deng, M.D
CONTACT
Nanjing First Hospital, Nanjing Medical University
Other
Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
Acronym: EVTRNA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07379190
Brain Diseases, Brain Infarction
Weifang, China/Shandong Province, China
View Trial DetailsNCT05911568
Brain Diseases, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT06658197
Brain Diseases, Cardiovascular Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT05578300
Brain Diseases, Cardiovascular Diseases
Linyi, Shandong, China
View Trial Details